At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,421 enrolled
Drug / intervention
doxycycline (Oracea®) 40 mg modified release as monotherapy +1 moredrug
Likely dose
doxycycline (Oracea®) 40 mg modified release as monotherapyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea
In Brief
A Phase 4 clinical trial evaluating doxycycline (Oracea®) 40 mg modified release as monotherapy and doxycycline (Oracea®) 40 mg modified release as add-on therapy for Rosacea. Completed, enrolled 1,421 participants across 1 site.
Detailed Summary
The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedMay 2009
Primary CompletionOct 2009
TodayJul 2026
First PostedMay 4, 2009
Enrollment StartApr 1, 2009
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.2 years ago
Interventions
doxycycline (Oracea®) 40 mg modified release as monotherapydrug
Take once daily in the morning
doxycycline (Oracea®) 40 mg modified release as add-on therapydrug
Take once daily in the morning